EMG
CLDX icon

Ellington Management Group’s Celldex Therapeutics CLDX Stock Holding History

Ellington Management Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-829
Closed -$131K – 616
2015
Q3 		$131K Buy
+829
New +$235K 0.04% 636
2015
Q1 		– Sell
-787
Closed -$215K – 698
2014
Q4 		$215K Buy
+787
New +$196K 0.07% 430
2014
Q2 		– Sell
-687
Closed -$182K – 474
2014
Q1 		$182K Buy
+687
New +$263K 0.05% 542
2013
Q3 		– Sell
-1,593
Closed -$373K – 783
2013
Q2 		$373K Buy
+1,593
New +$314K 0.07% 425

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Ellington Management Group's CLDX Position: Q4 2015 in Review

Ellington Management Group sold out of Celldex Therapeutics (CLDX) in Q4 2015, closing a stake of 829 shares — an estimated $131K sold.

Ellington Management Group first reported a position in CLDX in Q2 2013 and held it in 4 quarters. The position peaked at $373K in Q2 2013. 171 funds tracked by Wall St. Rank hold CLDX as of Q4 2015.

  • Ellington Management Group reported no remaining Celldex Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Ellington Management Group sold 829 Celldex Therapeutics shares in Q4 2015, an estimated $131K.
  • Ellington Management Group first reported a position in Celldex Therapeutics in Q2 2013 and held it in 4 quarters.
  • Ellington Management Group's Celldex Therapeutics position peaked at $373K in Q2 2013.
  • 171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2015.

Based on Ellington Management Group's 13F filing for Q4 2015, filed 16 Feb 2016.